Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 9;16(12):29345-56.
doi: 10.3390/ijms161226176.

The Safety Evaluation of Salvianolic Acid B and Ginsenoside Rg1 Combination on Mice

Affiliations

The Safety Evaluation of Salvianolic Acid B and Ginsenoside Rg1 Combination on Mice

Qun Zhao et al. Int J Mol Sci. .

Abstract

Our previous study indicated that the combination of salvianolic acid B (SalB) and ginsenoside Rg1 (Rg1), the main components of Salvia miltiorrhizae and Panax notoginseng, improves myocardium structure and ventricular function in rats with ischemia/reperfusion injury. The present study aimed to determine the safety of the combined SalB and Rg1 (SalB-Rg1) in mice. The safety of SalB-Rg1 was evaluated through acute toxicity and repeated-dose toxicity. In the acute toxicity study, the up and down procedure was carried out firstly, and then, the Bliss method was applied. In the toxicity study for seven-day repeated treatment of SalB-Rg1, forty Kunming mice were randomly divided into four groups. The intravenous median lethal dose (LD50) of the SalB-Rg1 combination was 1747 mg/kg using the Bliss method. For both the acute toxicity study and the seven-day repeated toxicity study, SalB-Rg1 did not induce significant abnormality on brain, heart, kidney, liver and lung structure at any dose based on H&E stain. There were no significant changes related to the SalB-Rg1 toxicity detected on biochemical parameters for two kinds of toxicity studies. The LD50 in mice was 1747 mg/kg, which was more than one hundred times higher than the effective dose. Both studies of acute toxicity and seven-day repeated dose toxicity indicated the safety of the SalB-Rg1 combination.

Keywords: acute toxicity; ginsenoside Rg1; repeated toxicity; safety; salvianolic acid B.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative chromatograms of salvianolic acid B (SalB) and ginsenoside Rg1 (Rg1). (A) The purity of SalB was 98.46%; and (B) the purity of Rg1 was 98.35%.
Figure 2
Figure 2
The sequence of the up and down procedure. The surviving animals are marked as green circles and the dead animals as a red cross. The initial dose was 175 mg/kg of the SalB-Rg1 combination.
Figure 3
Figure 3
The survival curve for acute toxicity. All of the deaths occurred within 24 h after intravenous administration of SalB-Rg1.
Figure 4
Figure 4
Representative histological pictures of heart (A), kidney (B), spleen (C), brain (D), lung (E) and liver (F) staining with H&E in the acute toxicity study (magnification 400×).
Figure 5
Figure 5
Representative histological pictures of heart (A), kidney (B), spleen (C), brain (D), lung (E) and liver (F) staining with H&E in the seven-day repeated toxicity study (magnification 400×).

Similar articles

Cited by

References

    1. Chun-Sheng L., Hsiao-Meng Y., Yun-Hsiang H., Chun P., Chi-Fen S. Radix salviae miltiorrhizae and Rhizoma ligustici wallichii in coronary heart disease. Chin. Med. J. 1978;4:43–46. - PubMed
    1. Shang Q., Xu H., Liu Z., Chen K., Liu J. Oral Panax notoginseng preparation for coronary heart disease: A systematic review of randomized controlled trials. Evid. Based Complement. Alternat. Med. 2013;2013 doi: 10.1155/2013/940125. - DOI - PMC - PubMed
    1. Deng Y., Yang M., Xu F., Zhang Q., Zhao Q., Yu H., Li D., Zhang G., Lu A., Cho K., et al. Combined salvianolic acid B and ginsenoside Rg1 exerts cardioprotection against ischemia/reperfusion injury in rats. PLoS ONE. 2015;10:e0135435. doi: 10.1371/journal.pone.0135435. - DOI - PMC - PubMed
    1. Guengerich F.P. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab. Pharmacokinet. 2011;26:3–14. doi: 10.2133/dmpk.DMPK-10-RV-062. - DOI - PMC - PubMed
    1. Yang T.Y., Wei J.C., Lee M.Y., Chen C.M., Ueng K.C. A randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of Fufang Danshen (Salvia miltiorrhiza) as add-on antihypertensive therapy in Taiwanese patients with uncontrolled hypertension. Phytother. Res. 2012;26:291–298. doi: 10.1002/ptr.3548. - DOI - PubMed

Publication types